Literature DB >> 35239537

Driveline Infection in Left Ventricular Assist Device Patients: Effect of Standardized Protocols, Pathogen Type, and Treatment Strategy.

Heidi S Lumish1, Barbara Cagliostro, Lorenzo Braghieri, Bruno Bohn, Giulio M Mondellini, Karen Antler, Vivian Feldman, Audrey Kleet, Jennifer Murphy, Melie Tiburcio, Kathryn Fidlow, Douglas Jennings, Gabriel T Sayer, Koji Takeda, Yoshifumi Naka, Ryan T Demmer, Justin G Aaron, Nir Uriel, Paolo C Colombo, Melana Yuzefpolskaya.   

Abstract

Driveline infection (DLI) is common after left ventricular assist device (LVAD). Limited data exist on DLI prevention and management. We investigated the impact of standardized driveline care initiatives, specific pathogens, and chronic antibiotic suppression (CAS) on DLI outcomes. 591 LVAD patients were retrospectively categorized based on driveline care initiatives implemented at our institution (2009-2019). Era (E)1: nonstandardized care; E2: standardized driveline care protocol; E3: addition of marking driveline exit site; E4: addition of "no shower" policy. 87(15%) patients developed DLI at a median (IQR) of 403(520) days. S. aureus and P. aeruginosa were the most common pathogens. 31 (36%) of DLI patients required incision and drainage (I&D) and 5 (5.7%) device exchange. P. aeruginosa significantly increased risk for initial I&D (HR 2.7, 95% CI, 1.1-6.3) and recurrent I&D or death (HR 4.2, 95% CI, 1.4-12.5). Initial I&D was associated with a significant increased risk of death (HR 2.92 (1.33-6.44); P = 0.008) when compared to patients who did not develop DLI. Implementation of standardized driveline care protocol (E2) was associated with increased 2-year freedom from DLI compared to nonstandardized care (HR 0.36, 95% CI, 0.2-0.6, P < 0.01). Additional preventive strategies (E3&E4) showed no further reduction in DLI rates. 57(65%) DLI patients received CAS, 44% of them required escalation to intravenous antibiotics and/or I&D. Presence of P. aeruginosa DLI markedly increased risk for I&D or death. Conditional survival of patients progressing to I&D is diminished. Standardized driveline care protocol was associated with a significant reduction in DLI, while additional preventive strategies require further testing.
Copyright © 2022 by the American Society for Artificial Internal Organs.

Entities:  

Year:  2022        PMID: 35239537      PMCID: PMC9469917          DOI: 10.1097/MAT.0000000000001690

Source DB:  PubMed          Journal:  ASAIO J        ISSN: 1058-2916            Impact factor:   3.826


  31 in total

1.  Heart transplantation outcomes in patients with continuous-flow left ventricular assist device-related complications.

Authors:  Mohammed A Quader; Luke G Wolfe; Vigneshwar Kasirajan
Journal:  J Heart Lung Transplant       Date:  2014-07-22       Impact factor: 10.247

2.  Intrapericardial Left Ventricular Assist Device for Advanced Heart Failure.

Authors:  Joseph G Rogers; Francis D Pagani; Antone J Tatooles; Geetha Bhat; Mark S Slaughter; Emma J Birks; Steven W Boyce; Samer S Najjar; Valluvan Jeevanandam; Allen S Anderson; Igor D Gregoric; Hari Mallidi; Katrin Leadley; Keith D Aaronson; O H Frazier; Carmelo A Milano
Journal:  N Engl J Med       Date:  2017-02-02       Impact factor: 91.245

Review 3.  Risk of left ventricular assist device driveline infection: A systematic literature review.

Authors:  Noelle V Pavlovic; Tania Randell; Tim Madeira; Steven Hsu; Radoslav Zinoviev; Martha Abshire
Journal:  Heart Lung       Date:  2018-12-17       Impact factor: 2.210

4.  Substantial Reduction in Driveline Infection Rates With the Modification of Driveline Dressing Protocol.

Authors:  Matthew M Lander; Nicole Kunz; Elizabeth Dunn; Andrew D Althouse; Kathy Lockard; Michael A Shullo; Robert L Kormos; Jeffrey J Teuteberg
Journal:  J Card Fail       Date:  2018-08-08       Impact factor: 5.712

5.  An early investigation of outcomes with the new 2018 donor heart allocation system in the United States.

Authors:  Rebecca Cogswell; Ranjit John; Jerry D Estep; Sue Duval; Ryan J Tedford; Francis D Pagani; Cindy M Martin; Mandeep R Mehra
Journal:  J Heart Lung Transplant       Date:  2019-11-20       Impact factor: 10.247

6.  Device exchange from HeartMate II to HeartMate 3 left ventricular assist device.

Authors:  Koji Takeda; Hiroo Takayama; Joseph Sanchez; Marisa Cevasco; Melana Yuzefpolskaya; Paolo C Colombo; Yoshifumi Naka
Journal:  Interact Cardiovasc Thorac Surg       Date:  2019-09-01

7.  Efficacy and safety of chronic antimicrobial suppression therapy for left ventricular assist device driveline infections: A single-center descriptive experience.

Authors:  Christopher Radcliffe; Natnael Doilicho; Yu Si Niu; Matthew Grant
Journal:  Transpl Infect Dis       Date:  2020-07-06       Impact factor: 2.228

8.  The Society of Thoracic Surgeons Intermacs 2019 Annual Report: The Changing Landscape of Devices and Indications.

Authors:  Jeffrey J Teuteberg; Joseph C Cleveland; Jennifer Cowger; Robert S Higgins; Daniel J Goldstein; Mary Keebler; James K Kirklin; Susan L Myers; Christopher T Salerno; Josef Stehlik; Felix Fernandez; Vinay Badhwar; Francis D Pagani; Pavan Atluri
Journal:  Ann Thorac Surg       Date:  2020-03       Impact factor: 4.330

Review 9.  Prevention and early treatment of driveline infections in ventricular assist device patients - The DESTINE staging proposal and the first standard of care protocol.

Authors:  Alexander M Bernhardt; Thomas Schlöglhofer; Volker Lauenroth; Florian Mueller; Marcus Mueller; Alexandra Schoede; Christian Klopsch
Journal:  J Crit Care       Date:  2019-12-17       Impact factor: 3.425

10.  Clinical manifestations and management of left ventricular assist device-associated infections.

Authors:  Juhsien Jodi C Nienaber; Shimon Kusne; Talha Riaz; Randall C Walker; Larry M Baddour; Alan J Wright; Soon J Park; Holenarasipur R Vikram; Michael R Keating; Francisco A Arabia; Brian D Lahr; M Rizwan Sohail
Journal:  Clin Infect Dis       Date:  2013-08-13       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.